Kala Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Kala Pharmaceuticals generated cash of -$27,927,000, which is more than the previous year. Cash used in financing activities reached the amount of $8,506,000 last year. Net change in cash is therefore -$19,850,000.
Cash Flow
| 2013 | -10.84M | -841K | 15.95M |
|---|---|---|---|
| 2015 | -15.08M | -252K | 10.48M |
| 2016 | -27.34M | -153K | 67.21M |
| 2017 | -34.09M | -480K | 103.69M |
| 2018 | -54.12M | -1.57M | 124.10M |
| 2019 | -92.72M | -1.33M | 8.98M |
| 2020 | -90.69M | -78.20M | 160.62M |
| 2021 | -108.23M | 70.80M | 42.55M |
| 2022 | -78.90M | 62.71M | -7.94M |
| 2023 | -27.92M | -429K | 8.50M |
0JQ2.L Cash Flow Statement (2013 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 70.74M | 94.87M | 89.75M | 98.03M | 183.10M | 114.69M | 45.58M | 5.75M | 10.72M | 0 |
Operating activities | ||||||||||
Net income | -42.19M | -44.82M | -142.60M | -104.32M | -94.34M | -66.73M | -42.21M | -33.16M | -16.68M | -10.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 303K | 537K | 975K | 912K | 843K | 955K | 287K | 297K | 330K | 201K |
Stock-based compensation expense | 7.46M | 7.00M | 16.08M | 13.31M | 9.99M | 0 | 3.57M | 2.06M | 638K | 304K |
| Deferred income tax benefit | 7.46M | 7.00M | 16.08M | 13.31M | 9.99M | 0 | 3.57M | 2.06M | 638K | 304K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 78K | 15.13M | -5.75M | 1.95M | -11.56M | -157.85M | 0 | 0 | 36K | -263K |
Inventories | 7.54M | 1.70M | -6.25M | -2.36M | -4.27M | -3.86M | 0 | 0 | -571K | 0 |
Accounts payable | -1.90M | -2.07M | 3.23M | -924K | -2.77M | 4.08M | 205K | -343K | 911K | 0 |
Cash generated by operating activities | -27.92M | -78.90M | -108.23M | -90.69M | -92.72M | -54.12M | -34.09M | -27.34M | -15.08M | -10.84M |
Investing activities | ||||||||||
Purchases Of Investments | -9.86M | -4.99M | 0 | -113.59M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -610K | -313K | -886K | -1.94M | -1.33M | -1.57M | -480K | -153K | -252K | -789K |
Acquisitions Net | 0 | 62.90M | -4.65M | 2.07M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -429K | 62.71M | 70.80M | -78.20M | -1.33M | -1.57M | -480K | -153K | -252K | -841K |
Financing activities | ||||||||||
Common Stock Issued | 18.53M | 31.79M | 42.81M | 158.55M | 8.42M | 70.76M | 94.00M | 67.52M | 104K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 365K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -10M | -40.03M | -263K | -32K | -30K | -21.84M | 8.88M | -1.33M | 5M | -457K |
Cash used in financing activities | 8.50M | -7.94M | 42.55M | 160.62M | 8.98M | 124.10M | 103.69M | 67.21M | 10.48M | 15.95M |
Net Change In Cash | -19.85M | -24.13M | 5.12M | -8.27M | -85.07M | 68.40M | 69.11M | 39.71M | -4.86M | 5.31M |
Cash at end of period | 50.89M | 70.74M | 94.87M | 89.75M | 98.03M | 183.10M | 114.69M | 45.47M | 5.86M | 5.31M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |